Can I get the same effect from broccoli?

Cruciferous vegetables supply indole-3-carbinol, the precursor, but reaching trial-level DIM exposure from food alone is not realistic.

Will DIM lower my oestrogen?

No. It redirects how oestrogen is metabolised rather than reducing how much you produce.

Why is my urine dark?

A known, harmless effect of DIM. It resolves when you stop.

Outcome

Moderate Evidence

Effectiveness 3/5

DIM for Estrogen Metabolism Support

At 100-300 mg/day DIM measurably increases 2-hydroxyoestrone relative to 16-alpha-hydroxyoestrone in urine. This is the clearest thing DIM does — and also the limit of what has been demonstrated.

Overview

DIM is the compound your stomach makes from indole-3-carbinol in broccoli and other brassicas, and its effect on oestrogen metabolism is measurable. In a randomised pilot trial, DIM significantly raised the urinary 2-hydroxyoestrone to 16-alpha-hydroxyoestrone ratio versus placebo.

That ratio is the standard laboratory readout of which metabolic pathway your oestrogen takes. Shifting it upward means more oestrogen leaving via the 2-hydroxy route, which is the shift most researchers regard as favourable. What cannot be claimed is a health outcome. The trial measured urinary metabolites, not symptoms or disease endpoints, and a shifted ratio remains a surrogate marker until clinical trials show it changes how people actually do.

Verdict

Likely effective

Randomised pilot data confirm DIM shifts the 2:16-alpha-hydroxyoestrone ratio and raises 2-hydroxyoestrone. The endpoint is a urinary marker, not a clinical outcome.

How It Works

Oestradiol is cleared through hydroxylation, and the branch point matters. The CYP1A1 route produces 2-hydroxyoestrone, a weakly active metabolite; the CYP1B1 route produces 16-alpha-hydroxyoestrone, which retains more oestrogenic activity.

DIM acts on the aryl hydrocarbon receptor and preferentially induces CYP1A1, pushing more oestrogen down the 2-hydroxy branch. That is why the ratio moves rather than total oestrogen falling; DIM redirects clearance instead of blocking production. This distinction matters for expectations. DIM is not an aromatase inhibitor and does not lower oestradiol in the way an anti-oestrogen drug would. It changes the mix of what oestrogen becomes on its way out.

Primary target: Aryl hydrocarbon receptor; induces CYP1A1
Metabolic shift: More 2-hydroxyoestrone, relatively less 16-alpha-hydroxyoestrone
What it does not do: Does not inhibit aromatase or reduce oestrogen production
Best-fit user: Adults tracking the 2:16 ratio as a metabolism marker
Poor fit: Anyone expecting a drop in total oestradiol

Dosing & Protocol

Trials use 108 to 300 mg daily of absorption-enhanced DIM. Crystalline DIM is very poorly absorbed, so the microencapsulated or bioavailability-enhanced form used in research is the relevant product, and the label dose often refers to a complex rather than pure DIM.

Context	Dose	Form	Timing
Pilot trial dose	108 mg daily	Absorption-enhanced DIM	Once daily with food
Common commercial range	100-200 mg daily	Microencapsulated DIM	With a fat-containing meal
Higher research doses	300 mg daily	Bioavailability-enhanced DIM	Split into two doses
Assessment window	4-12 weeks	Enhanced formulation	Daily

1
Decide what you will measure· Week 0
A urinary 2:16-alpha-hydroxyoestrone ratio is the endpoint the evidence supports. Without it there is nothing to judge.
2
Choose an enhanced formulation· Before starting
Plain crystalline DIM absorbs poorly; look for microencapsulated or bioavailability-enhanced products.
3
Take 100-200 mg daily with food· Weeks 1-12
DIM is fat-soluble, so a meal containing fat improves absorption.
4
Expect harmless urine discolouration· Days 1-7
A dark amber or brownish tint is common and is not a warning sign.
5
Retest the ratio at 12 weeks· Week 12
Use the same laboratory and collection method. If nothing moved, stop rather than escalating.

Speak to your oncologist first if you have a hormone-sensitive cancer history

The trials were conducted in exactly this population under supervision. DIM alters oestrogen handling and interacts with tamoxifen metabolism, so it is not a self-directed decision.

Evidence

The linked randomised pilot trial in postmenopausal women found that DIM raised urinary 2-hydroxyoestrone and significantly increased the 2:16-alpha-hydroxyoestrone ratio against placebo. It is small, at nineteen participants, and explicitly exploratory.

Randomised pilot trial linked to this pairing.

Pilot Study: Effect of 3,3'-Diindolylmethane Supplements on Urinary Hormone Metabolites in Postmenopausal Women with a History of Early-Stage Breast Cancer

Score: 4/10

2004

rct

n=19

Dalessandri KM, Firestone GL, Fitch MD +2 more

DIM significantly increased the 2-hydroxyoestrone to 16-alpha-hydroxyoestrone ratio versus placebo.

View source

Best available evidence: Randomised placebo-controlled pilot trial, n=19
Typical effect: Higher urinary 2-hydroxyoestrone and increased 2:16 ratio
Studied dose: 108 mg daily of absorption-enhanced DIM
Time to effect: Measured over weeks of daily use
Main limitation: Very small sample; surrogate urinary endpoint only

Safety

Short-term tolerability is good at standard doses. Headache, nausea and a harmless darkening of the urine are the usual reports, and gas or bloating occurs in some people.

Cautions

Harmless dark amber or brown urine

Headache and nausea, usually dose-related

Avoid in pregnancy and breastfeeding

Discuss before use with any hormone-sensitive condition

Long-term safety data beyond a year are limited

Interactions & Conflicts

DIM induces cytochrome P450 enzymes, which is precisely how it works and also the source of its interactions. Anything cleared by CYP1A2 or CYP3A4 can have its levels shifted.

Interacts with	Severity	Mechanism	Action
Tamoxifen	high	DIM lowered active endoxifen concentrations in a randomised trial	Do not combine without your oncologist's agreement
CYP1A2 substrates	moderate	Enzyme induction can lower drug levels	Review your medication list with a pharmacist first
Hormonal contraceptives and HRT	moderate	Altered oestrogen metabolism may change exposure	Discuss with your prescriber before starting
Other oestrogen-modulating supplements	low	Overlapping and unpredictable combined effects	Use one at a time so you can interpret the result

References

Dalessandri KM et al. Pilot study: effect of 3,3-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.

About DIM

3,3-Diindolylmethane

3,3-diindolylmethane forms in the stomach from indole-3-carbinol in broccoli and related vegetables. It modulates cytochrome P450 enzymes involved in oestrogen hydroxylation and has been studied in cervical dysplasia, prostate lesions and hormonal symptom management.

About Estrogen Metabolism Support

Estrogens are metabolised in the liver through two sequential phases: hydroxylation by cytochrome P450 enzymes into 2-, 4- and 16-hydroxy metabolites, followed by conjugation via methylation, glucuronidation and sulfation before excretion. The 2-hydroxy pathway is generally regarded as favourable and the 4-hydroxy pathway as potentially genotoxic, since 4-hydroxyestradiol can form DNA-damaging quinones. The gut microbiome adds a further loop: bacterial beta-glucuronidase deconjugates estrogen in the intestine and allows reabsorption, which is why fibre intake and microbial composition influence circulating levels. This biology has been converted into a supplement category built around DIM and I3C, which do shift the 2:16 hydroxyestrone ratio in trials. The problem is that this ratio is a surrogate whose relationship to clinical outcomes such as breast cancer risk has not held up consistently, and no supplement has demonstrated an outcome benefit.

Other supplements for Estrogen Metabolism Support

Indole-3-Carbinol

Also supports

Estrogen Balance

Information is for educational use. Always consult your healthcare provider before starting a supplement.